Traders Buy Shares of Jazz Pharmaceuticals (JAZZ) on Weakness on Insider Selling

Investors purchased shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) on weakness during trading hours on Monday after an insider sold shares in the company. $25.29 million flowed into the stock on the tick-up and $14.27 million flowed out of the stock on the tick-down, for a money net flow of $11.02 million into the stock. Of all equities tracked, Jazz Pharmaceuticals had the 26th highest net in-flow for the day. Jazz Pharmaceuticals traded down ($0.11) for the day and closed at $155.96Specifically, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $139.99, for a total transaction of $27,998.00. Following the transaction, the executive vice president now owns 21,469 shares of the company’s stock, valued at $3,005,445.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew P. Young sold 700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $152.16, for a total transaction of $106,512.00. The disclosure for this sale can be found here. Insiders have sold 14,657 shares of company stock valued at $2,187,294 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Several brokerages have weighed in on JAZZ. Piper Jaffray reaffirmed a “buy” rating and set a $201.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, March 1st. HC Wainwright reaffirmed a “neutral” rating and set a $160.00 price target (up previously from $150.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 23rd. B. Riley reaffirmed a “buy” rating and set a $206.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, December 20th. Seaport Global Securities set a $175.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Friday, April 6th. Finally, Deutsche Bank set a $170.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, January 16th. Six research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Jazz Pharmaceuticals has an average rating of “Buy” and a consensus price target of $180.78.

The company has a current ratio of 3.29, a quick ratio of 3.15 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $9,333.52, a P/E ratio of 16.31, a price-to-earnings-growth ratio of 0.82 and a beta of 0.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the consensus estimate of $2.73 by ($0.15). Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. The company had revenue of $436.40 million during the quarter, compared to analysts’ expectations of $440.91 million. analysts anticipate that Jazz Pharmaceuticals will post 11.48 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. US Bancorp DE increased its position in Jazz Pharmaceuticals by 49.5% in the fourth quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock worth $147,000 after purchasing an additional 360 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Jazz Pharmaceuticals by 29.4% in the third quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock worth $257,000 after purchasing an additional 400 shares during the last quarter. Allianz Asset Management GmbH increased its position in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Allianz Asset Management GmbH now owns 109,279 shares of the specialty pharmaceutical company’s stock worth $14,715,000 after purchasing an additional 488 shares during the last quarter. Highstreet Asset Management Inc. increased its position in Jazz Pharmaceuticals by 20.0% in the fourth quarter. Highstreet Asset Management Inc. now owns 3,488 shares of the specialty pharmaceutical company’s stock worth $470,000 after purchasing an additional 581 shares during the last quarter. Finally, Renaissance Group LLC increased its position in Jazz Pharmaceuticals by 0.6% in the fourth quarter. Renaissance Group LLC now owns 108,401 shares of the specialty pharmaceutical company’s stock worth $14,596,000 after purchasing an additional 670 shares during the last quarter. Institutional investors own 91.21% of the company’s stock.

WARNING: This story was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2018/04/16/traders-buy-shares-of-jazz-pharmaceuticals-jazz-on-weakness-on-insider-selling.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply